As of November 6, 2026, one holder's latest Schedule 13D or 13G filing report owning 5% or more of Neumora Therapeutics, Inc. The largest reported stake is ARCH Venture Fund XII, L.P.'s, at 18.7%. 7 filings are on record since August 11, 2025 (Schedule 13D/A, April 1, 2026).
Sell to companies like Neumora Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Holder: K2 HealthVentures Equity Trust LLC · Percent: 3.1% · SCHEDULE 13G/A
- · Reporting person: Invus Public Equities, L.P. · Sole voting: 7,740,030 · Shared voting: 0 · Sole dispositive: 7,740,030 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-04
- · Reporting person: ARCH Venture Fund VII, L.P. · Sole voting: 0 · Shared voting: 33,847,838 · Sole dispositive: 0 · Shared dispositive: 33,847,838 · SCHEDULE 13D/A, 2026-04-01
- · Holder: Raymond Debbane · Percent: 5.4% · SCHEDULE 13G
- · Holder: K2 HealthVentures Equity Trust LLC · Percent: 5.01% · SCHEDULE 13G/A
Neumora Therapeutics, Inc. has 7 Schedule 13D or 13G filings on record since 2025-08-11. 1 holder's latest filing reports 5% or more of common stock, par value $0.0001 per share. Each figure below is the holder's own, as filed, with the filing linked.
Layoffs on record: 1 filing or notice, latest 2026-06-15 (layoff filings and notices).
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| ARCH Venture Fund XII, L.P. | 18.7% | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 | 2026-03-30 |
| 4.7% | 8,497,822 | SCHEDULE 13G/A, 2026-05-04 | 2026-03-31 | |
| K2 HealthVentures Equity Trust LLC | 3.1% | 5,790,453 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind Neumora Therapeutics, Inc. and the warning signs.
Free to see. No signup.
Keep reading
More on Neumora Therapeutics, Inc. and the records around it.
Neumora Therapeutics, Inc. elsewhere on the record
- Leadership changes Aug 2026
- Layoff notices Jun 2026
- Who owns it
Companies that share a holder
- K2 HealthVentures Equity Trust LLC also filed stake reports on 1 other company: Alto Neuroscience, Inc. (Feb 2026)
- ARCH Venture Fund VII, L.P. also filed stake reports on 5 other companies: City Therapeutics, Inc. (Oct 2026), Parabilis Medicines, Inc. (Aug 2026), Seaport Therapeutics, Inc. (May 2026)
- Invus Public Equities, L.P. also filed stake reports on 24 other companies: City Therapeutics, Inc. (Oct 2026), Yarrow Bioscience, Inc. (Sep 2026), Abivax S.A. (Aug 2026)
Watch Neumora Therapeutics, Inc.
Get an email when Neumora Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Neumora Therapeutics, Inc.?
Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News
A Full Report on Neumora Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Neumora Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
9 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| ARCH Venture Fund VII, L.P. | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Fund VIII Overage, L.P. | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Fund X, L.P. | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Fund X Overage, L.P. | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Fund XII, L.P. | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Partners VII, L.P. | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Partners X, L.P. | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Partners X Overage, L.P. | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Partners XII, L.P. | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Partners VII, LLC | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Partners VIII, LLC | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Partners X, LLC | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| ARCH Venture Partners XII, LLC | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| Robert Nelsen | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| Keith Crandell | 0 | 33,847,838 | 0 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| Clinton Bybee | 0 | 3,708,794 | 0 | 3,708,794 | SCHEDULE 13D/A, 2026-04-01 |
| Kristina Burow | 117,581 | 33,847,838 | 117,581 | 33,847,838 | SCHEDULE 13D/A, 2026-04-01 |
| Steven Gillis | 0 | 31,526,272 | 0 | 31,526,272 | SCHEDULE 13D/A, 2026-04-01 |
| Invus Public Equities, L.P. | 7,740,030 | 0 | 7,740,030 | 0 | SCHEDULE 13G/A, 2026-05-04 |
| Invus Public Equities Advisors, LLC | 7,740,030 | 0 | 7,740,030 | 0 | SCHEDULE 13G/A, 2026-05-04 |
| Invus Global Management, LLC | 7,740,030 | 0 | 7,740,030 | 0 | SCHEDULE 13G/A, 2026-05-04 |
| Siren, L.L.C. | 7,740,030 | 0 | 7,740,030 | 0 | SCHEDULE 13G/A, 2026-05-04 |
| Avicenna Life Sci Master Fund LP | 757,792 | 0 | 757,792 | 0 | SCHEDULE 13G/A, 2026-05-04 |
| Avicenna Life Sci Master GP LLC | 757,792 | 0 | 757,792 | 0 | SCHEDULE 13G/A, 2026-05-04 |
The latest filing identifies Neumora Therapeutics, Inc. by CUSIP 640979100 and gives its principal executive office as 260 Arsenal Place, Suite 1, Watertown, MA 02472 (SCHEDULE 13G/A, 2026-05-15).
What the percentages are based on
As of March 31, 2026, each of the Reporting Persons may be deemed to be the beneficial owner of the percentage of Shares listed on such Reporting Person's cover page.Raymond Debbane, SCHEDULE 13G/A, 2026-05-04
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-11 | K2 HealthVentures Equity Trust LLC | 6.6% | SCHEDULE 13G |
| 2025-10-29 | ARCH Venture Fund XII, L.P. | 20.7% | SCHEDULE 13D/A |
| 2026-02-17 | K2 HealthVentures Equity Trust LLC | 5.01% | SCHEDULE 13G/A |
| 2026-02-19 | Raymond Debbane | 5.4% | SCHEDULE 13G |
| 2026-04-01 | ARCH Venture Fund XII, L.P. | 18.7% | SCHEDULE 13D/A |
| 2026-05-04 | Raymond Debbane | 4.7% | SCHEDULE 13G/A |
| 2026-05-15 | K2 HealthVentures Equity Trust LLC | 3.1% | SCHEDULE 13G/A |
Questions about who owns Neumora Therapeutics, Inc.
Who owns Neumora Therapeutics, Inc.?
On this page, one holder's latest ownership filing reports 5% or more of Neumora Therapeutics, Inc.: ARCH Venture Fund XII, L.P. (18.7%, Schedule 13D/A, filed 2026-04-01).
When did ARCH Venture Fund XII, L.P. buy into Neumora Therapeutics, Inc.?
The filings give report dates, not purchase dates. The earliest filing from ARCH Venture Fund XII, L.P. on this page is the Schedule 13D/A, filed 2025-10-29, reporting 20.7%; its latest, Schedule 13D/A filed 2026-04-01, reports 18.7%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 7 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Also on the record for Neumora Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| August 14, 2026 | Leadership change: Paul L. Berns appointed, Chief Executive Officer | — | Leadership changes | Source |
Tools for this story
Each opens in a new tab, filled in for Neumora Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.